IRIS
PERSONENI, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.473
NA - Nord America 1.341
EU - Europa 356
Continente sconosciuto - Info sul continente non disponibili 163
SA - Sud America 33
AF - Africa 26
OC - Oceania 1
Totale 3.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.277
SG - Singapore 632
VN - Vietnam 281
CN - Cina 262
BD - Bangladesh 185
IT - Italia 158
FR - Francia 148
CA - Canada 29
HK - Hong Kong 28
BR - Brasile 16
DE - Germania 14
IN - India 14
MX - Messico 12
SC - Seychelles 12
JP - Giappone 11
SE - Svezia 8
JM - Giamaica 7
PH - Filippine 7
TH - Thailandia 7
GB - Regno Unito 6
IQ - Iraq 6
TR - Turchia 6
UZ - Uzbekistan 6
PK - Pakistan 5
PL - Polonia 5
AR - Argentina 4
CR - Costa Rica 4
ID - Indonesia 4
TW - Taiwan 4
ZA - Sudafrica 4
DK - Danimarca 3
EC - Ecuador 3
ES - Italia 3
KR - Corea 3
MA - Marocco 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BE - Belgio 2
BO - Bolivia 2
CO - Colombia 2
DO - Repubblica Dominicana 2
EG - Egitto 2
HN - Honduras 2
LB - Libano 2
MY - Malesia 2
PY - Paraguay 2
SV - El Salvador 2
AU - Australia 1
BG - Bulgaria 1
BJ - Benin 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CL - Cile 1
ET - Etiopia 1
FI - Finlandia 1
HU - Ungheria 1
IE - Irlanda 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
LT - Lituania 1
MR - Mauritania 1
NI - Nicaragua 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
RU - Federazione Russa 1
SY - Repubblica araba siriana 1
Totale 3.230
Salva come PNG Salva come JPEG
Città #
San Jose 340
Singapore 271
Council Bluffs 183
Lauterbourg 142
Ho Chi Minh City 92
Ashburn 90
Boardman 78
Hanoi 60
New York 34
Milan 32
Los Angeles 30
Rome 29
Buffalo 18
Santa Clara 18
Da Nang 16
Hong Kong 16
Dallas 12
Naples 9
Philadelphia 9
Haiphong 8
Montreal 8
Phoenix 7
Thomasville 7
Beijing 6
Frankfurt am Main 6
Pasadena 6
Tokyo 6
Toronto 6
Bologna 5
Charlotte 5
Denver 5
Hải Dương 5
Mexico City 5
Orem 5
The Bronx 5
Toms River 5
Atlanta 4
Can Tho 4
Catania 4
Champaign 4
Chicago 4
Johannesburg 4
Kingston 4
Las Vegas 4
London 4
Nashua 4
Orlando 4
Pageland 4
Querétaro 4
Sacramento 4
San Antonio 4
San Francisco 4
Shanghai 4
Slatington 4
Tashkent 4
Abbeville 3
Alexandria 3
Bangkok 3
Bari 3
Charleston 3
Chennai 3
Detroit 3
Dhaka 3
Easton 3
Genoa 3
Houston 3
Jakarta 3
Joliet 3
Miami 3
Mumbai 3
Nuremberg 3
Palermo 3
Queens 3
Reggio Calabria 3
Seattle 3
Thanh Mỹ Tây 3
Turin 3
Tân Tiến 3
Verona 3
Washington 3
Wichita 3
'Ewa Beach 2
Albuquerque 2
Anaheim 2
Ashland 2
Austin 2
Avon 2
Bakersfield 2
Baku 2
Blanchard 2
Boston 2
Bridgeport 2
Brimfield 2
Brooklyn 2
Bình Phước 2
Bến Tre 2
Casablanca 2
Chatsworth 2
Chula Vista 2
Conyers 2
Totale 1.771
Salva come PNG Salva come JPEG
Nome #
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression : a Phase II Study 79
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 74
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma 68
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 65
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 50
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 44
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 41
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 39
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 38
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 37
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 33
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 33
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 33
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab : A Fluorescent In situ Hybridization Study 32
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 32
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 31
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 31
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 31
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 30
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 30
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC 30
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 30
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma 30
Multidisciplinary Tumor Board in the Management of Patients with Colorectal Liver Metastases: A Single-Center Review of 847 Patients 30
Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer 30
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer : the VanGogh study 29
ARQ 087, an oral pan- fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced and/or metastatic intrahepatic cholangiocarcinoma (iCCA) 29
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 29
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma 28
Which choice of therapy when many are available? - Current systemic therapies for advanced hepatocellular carcinoma 28
Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study 27
Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: shedding light on the preclinical rationale and clinical trials 27
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 27
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 27
A Comparative Study of Methyl-BEAMing and Droplet Digital PCR for MGMT Gene Promoter Hypermethylation Detection 27
Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study 26
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy 26
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 26
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 26
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 26
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 26
Achievements in systhemic therapies in the pre-genomic era in metastatic breast cancer 25
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 25
Hepatocellular carcinoma: a global disease in need of individualized treatment strategies 25
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 25
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 25
Role of stereotactic body radiation therapy in the management of oligometastatic pancreatic cancer single institution experience 24
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 24
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 24
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study 23
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 23
Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives 22
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 22
Progression of Colorectal Liver Metastases from the End of Chemotherapy to Resection: A New Contraindication to Surgery? 22
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 22
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 22
Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors 22
The impact of mass spectrometry multigenic platform on the management of metastatic colorectal patients 22
Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial 22
Hepatic intra-arterial injection of Yttrium-loaded microspheres for liver metastasis secondary to colorectal cancer: best soups are sometimes made from old recipes 21
Advanced colorectal liver metastases and surgery after preoperative chemotherapy : is response-based selection enough? 21
SYSTEMIC TREATMENT OF HCC IN SPECIAL POPULATIONS 21
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 21
Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications 21
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab 21
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 21
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 21
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study 20
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 20
Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment 20
Biomarkers in Hepatocellular Carcinoma-Letter 20
Cabozantinib for the treatment of hepatocellular carcinoma 20
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 20
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer : a safe and effective approach 19
COVID-19 and liver cancer clinical trials: not everything is lost 19
Reply to Y. Pointreau et al 19
Shaping the landscape of immune oncology in hepatocellular carcinoma 19
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score 19
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity? 18
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 18
Diagnostic accuracy of 11C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 18
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 18
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 17
Regorafenib for the treatment of unresectable hepatocellular carcinoma 17
Metabolic switch in hepatocellular carcinoma patients treated with sorafenib: a proof-of-concept trial 17
Tivantinib for hepatocellular carcinoma 17
OncoAlert round table discussions: The global COVID-19 experience 17
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 17
Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells 17
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 17
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 17
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND) 17
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 17
Hepatocellular Carcinoma : A Global Disease in Need of Individualized Treatment Strategies 16
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy 16
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 16
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 16
Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study 16
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice 16
Sorafenib in Hepatitis C Virus-Negative Patients With Hepatocellular Carcinoma: Don't Throw the Baby Out With the Bathwater! 16
Totale 2.608
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.032
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.032
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20262.719 0 0 0 0 313 363 568 275 482 240 328 150
2026/2027674 571 103 0 0 0 0 0 0 0 0 0 0
Totale 3.393